For examples, either DZNep or GSK126 administration promoted the anti-tumor effect of TopoII inhibitor doxorubicin against BRG1 and EGFR mutant lung cancer, suggesting an opportunity for combination of traditional chemotherapy medicines and EZH2 inhibitors in NSCLC [61]. Here, EZH2 is linked to non-small cell lung carcinoma.